On February 15, 2023 Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to reported its Phase II diagnostic 64Cu SARTATE trial (DISCO NCT044383041) for patients with known or suspected neuroendocrine tumours (NETs) has reached the fifty percent recruitment milestone, with 32 out of 63 participants enrolled and imaged (Press release, Clarity Pharmaceuticals, FEB 15, 2023, View Source [SID1234627297]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DISCO, which derives from "Diagnostic Imaging Study of 64Copper-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumours", is assessing the performance of Clarity’s SARTATE imaging product as a potential new way to help diagnose and manage NETs. It is a Phase II study in up to 63 patients with Gastroenteropancreatic NETs (GEP-NETs) across four sites in Australia, comparing the diagnostic performance of 64Cu SARTATE at 4 and 20 hours post-administration to the current standard of care, 68Ga DOTATATE, at one hour. The trial aims to build on earlier studies with SARTATE (Hicks, R. et al)2 which demonstrated that imaging at later time points, enabled by a longer half-life of 64Cu isotope in comparison to 68Ga, may lead to better identification of disease.
Clarity’s Executive Chairman, Dr Alan Taylor, commented, "We are pleased with the progress of our SARTATE product. There is a clear unmet need in the NET indication with misdiagnosis and delay in diagnosis remaining very common. The vast majority of patients have the cancer spread to distant parts of the body by the time of diagnosis, which significantly affects treatment outcomes for people with NETs. Clarity continues to build on the promising first-in-human data, indicating the safety and potential effectiveness of the product as a new way to detect NETs. Combined with the logistical and supply benefits of central manufacturing enabled by the use of Targeted Copper Theranostics, SARTATE holds promise of delivering timely and crucial diagnostic scans to patients and their treating staff, bringing us closer to our ultimate goal of improving treatment outcomes for children and adults with cancer."
About SARTATE
SARTATE is a next generation, highly targeted theranostic radiopharmaceutical. It is being developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumours (NETs). Like all Clarity products, the SARTATE product can be used with copper-64 (64Cu) for imaging (64Cu SARTATE) or copper-67 (67Cu) for therapy (67Cu SARTATE).
About NETs
NETs, also known as well-differentiated neuroendocrine neoplasms or carcinoids, represent a heterogeneous group of malignant transformations of cells of the diffuse neuroendocrine system3. They most commonly occur in the gastrointestinal tract (48%), lung (25%), and pancreas (9%), but may also originate in other areas, including the breast, prostate, thymus and skin4. NETs can either be benign or malignant, as well as non-functional and functional5. NETs traditionally have been considered uncommon; however, the incidence has been increasing as a worldwide phenomenon6. This increase is thought to be mostly related to improvements in the way NETs are diagnosed, including better imaging tests and endoscopy, and increased awareness of these tumours7.
Overall, it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year, and approximately 175,000 people are living with this diagnosis7. Patients with GEP-NETs present with subtle clinical symptoms, which can lead to a delay in diagnosis of up to 5–7 years, or result in inappropriate management8. As such, about 30-75% of NET patients have distant metastases at the time of diagnosis9. A 10-year relative survival rate for patients with metastatic GEP-NETs is 3–36%10.